Belimumab

Belimumab Brand Names- Benlysta | Benlysta SC

What is Belimumab

Belimumab is a human monoclonal antibody that inhibits B lymphocyte stimulator protein (BLyS). Inhibition of BLyS inhibits the survival of B cells including autoreactive B cells and reduces the differentiation of B cells into immunoglobulin-producing plasma cells.

Belimumab is indicated as an adjunct to standard therapy for the treatment of active, autoantibody-positive, systemic lupus erythematosus (SLE).

Standard SLE therapy includes corticosteroids, antimalarials, NSAIDs, and/or immunosuppressants (e.g., azathioprine, mycophenolate, or methotrexate). While the ACR and EULAR guidelines for the management of SLE do not mention the use of belimumab, these guidelines were published before the drug’s availability.

NICE guidelines recommend that belimumab only be used as add-on therapy if the patient has a Safety of Estrogen in Lupus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score of 10 or more despite standard treatment; continued belimumab treatment beyond 6 months is only recommended if the SELENA-SLEDAI score is reduced by 4 points or more.

Intravenous use of belimumab is associated with infusion-related reactions, and the symptoms of these reactions may overlap with those noted with hypersensitivity reactions.

Serious and sometimes fatal hypersensitivity reactions and infections have been reported in patients receiving biologic immunosuppressive agents, including both intravenous and subcutaneous belimumab.

Indications

  • systemic lupus erythematosus (SLE)

For the treatment of active, autoantibody-positive, systemic lupus erythematosus (SLE) in combination with standard therapy

Side Effects

  1. anaphylactic shock
  2. angioedema
  3. antibody formation
  4. anxiety
  5. bradycardia
  6. cystitis
  7. depression
  8. diarrhea
  9. dyspnea
  10. edema
  11. erythema
  12. fatigue
  13. fever
  14. headache
  15. hematoma
  16. hypotension
  17. infection
  18. infection
  19. influenza
  20. infusion-related reactions
  21. injection site reaction
  22. insomnia
  23. leukoencephalopathy
  24. leukopenia
  25. migraine
  26. myalgia
  27. nausea
  28. new primary malignancy
  29. pharyngitis
  30. pruritus
  31. rash
  32. sinusitis
  33. suicidal ideation
  34. urticaria

Monitoring Parameters

  • laboratory monitoring not necessary

Contraindications

  • Black patients
  • breast-feeding
  • contraception requirements
  • depression
  • geriatric
  • immunosuppression
  • infants
  • infection
  • infusion-related reactions
  • neonates
  • new primary malignancy
  • pregnancy
  • progressive multifocal leukoencephalopathy
  • psychiatric event
  • reproductive risk
  • requires an experienced clinician
  • serious hypersensitivity reactions or anaphylaxis
  • suicidal ideation
  • vaccination

Interactions

  • Cyclophosphamide
  • Live Vaccines
  • Ocrelizumab
  • Ofatumumab
  • Rituximab
  • Rituximab; Hyaluronidase
  • Tumor Necrosis Factor modifiers
15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856
Scroll to Top